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Acute respiratory distress syndrome (ARDS) continues to have significant mortality and morbidity. The only intervention
proven to reduce mortality is the use of lung-protective mechanical ventilation strategies, although such a strategy
may lead to problematic hypercapnia. Extracorporeal carbon dioxide removal (ECCO2R) devices allow uncoupling of
ventilation from oxygenation, thereby removing carbon dioxide and facilitating lower tidal volume ventilation. We
performed a systematic review to assess efficacy, complication rates, and utility of ECCO2R devices. We included rando-
mised controlled trials (RCTs), case–control studies and case series with 10 or more patients. We searched MEDLINE,
Embase, LILACS (Literatura Latino Americana em Ciências da Saúde), and ISI Web of Science, in addition to grey litera-
ture and clinical trials registries. Data were independently extracted by two reviewers against predefined criteria and
agreement was reached by consensus. Outcomes of interest included mortality, intensive care and hospital lengths of
stay, respiratory parameters and complications. The review included 14 studies with 495 patients (two RCTs and 12 obser-
vational studies). Arteriovenous ECCO2R was used in seven studies, and venovenous ECCO2R in seven studies. Available
evidence suggests no mortality benefit to ECCO2R, although post hoc analysis of data from the most recent RCT showed
an improvement in ventilator-free days in more severe ARDS. Organ failure-free days or ICU stay have not been shown to
decrease with ECCO2R. Carbon dioxide removal was widely demonstrated as feasible, facilitating the use of lower
tidal volume ventilation. Complication rates varied greatly across the included studies, representing technological
advances. There was a general paucity of high-quality data and significant variation in both practice and technol-
ogy used among studies, which confounded analysis. ECCO2R is a rapidly evolving technology and is an efficacious
treatment to enable protective lung ventilation. Evidence for a positive effect on mortality and other important clinical
outcomes is lacking. Rapid technological advances have led to major changes in these devices and together with vari-
ation in study design have limited applicability of analysis. Further well-designed adequately powered RCTs are
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Acute respiratory distress syndrome (ARDS) is associ-
ated with significant mortality and morbidity [1]. Tidal
recruitment, alveolar derecruitment and high inspiratory
volumes during mechanical ventilation add further insult
to already injured and failing lungs [2]. Few interven-
tions have been proven to reduce mortality, with the
notable exception of low tidal volume ventilation [3]. In
practice, lung-protective strategies involving low tidal
volume ventilation can prove difficult to implement,
often due to concerns of hypercapnia or its potential ad-
verse physiological consequences [4].
Extracorporeal carbon dioxide removal (ECCO2R) of-
fers a potentially attractive solution to this problem be-
cause carbon dioxide can be ‘dialysed’ out of the blood,
while the lungs are ventilated in a maximally protective
manner [5]. Techniques to achieve this have existed
since the late 1970s [6,7], but widespread uptake has
been limited due to the paucity of trial data, the de-
manding technical requirements of the technique and
concerns regarding complications [8]. More recently,
modern developments in ECCO2R technology have stimu-
lated renewed interest [9], particularly because of the po-
tential for safe use in nonspecialist centres. To define
current understanding of ECCO2R in patients with acute
respiratory failure and inform future randomised con-
trolled trials (RCTs), we performed a systematic review to
assess efficacy and complication rates of ECCO2R.
Review
Design
The systematic review protocol was published in the
PROSPERO database [10] and complies with Preferred
Reporting Items for Systematic reviews and Meta-
Analysis guidelines [11].
We searched the MEDLINE, Embase, LILACS (Litera-
tura Latino Americana em Ciências da Saúde) and ISI
Web of Science databases (1976 to January 2014) using
a strategy developed by a trained medical librarian, com-
bining medical subject headings and keywords such as
interventional lung assist, extracorporeal and ARDS (see
Additional file 1 for the full MEDLINE search strategy).
Citations were screened by title/abstract level, and if
they were potentially relevant the full text was retrieved
and reviewed by MF and JM. We also reviewed reference
lists of identified studies and relevant review papers.
The search of grey literature included Opengray, NHS
Evidence, National Institute of Clinical Evidence and the
Scottish Intercollegiate Guidelines Network. To identify
planned or current studies we examined major clinical trial
registries [12-14]. Novalung GmbH (Talheim, Germany),
who manufacture the interventional lung assist and iLA
Activve®, were consulted to identify any current studies.
The search strategy included no language restriction.Inclusion criteria were: type of study – RCT or observa-
tional (for example, case–control or case series) including
10 or more patients; type of participants – adult patients
(>18 years) with ARDS (or acute respiratory failure
in studies occurring prior to the American–European
Consensus Conference Committee definition of ARDS in
1994); type of interventions – arteriovenous or venove-
nous ECCO2R device; and type of outcomes – hospital or
ICU mortality, hospital or ICU length of stay, ventilator-
free days (VFDs), organ failure-free days, quantified car-
bon dioxide removal, and reported complications.
Study selection
Two authors (MF and JM) independently reviewed the
retrieved abstracts and assessed eligibility. Full-text arti-
cles were retrieved and assessed to confirm eligibility.
Disagreement was resolved by consensus with a third
author (DFM).
Data extraction
Data from included studies were independently ex-
tracted by MF and JM, using a pre-piloted data extrac-
tion form (Additional file 2). Disagreements were
resolved by a third author (BB). We extracted the follow-
ing data: study design, study and participant characteris-
tics, study intervention and setting, relevant outcome
data, and complications.
Assessment of methodological quality
Two authors (MF and JM) independently assessed meth-
odological quality. Observational studies were assessed
using the Critical Appraisal Skills Programme tools and,
for case series, a specific checklist [15,16]. RCTs were
assessed using the risk of bias domain-based evaluation
as described in the Cochrane Handbook for Systematic
Reviews of Interventions [17].
Search results
The search identified 147 citations from database
searches and reference lists (Figure 1). Following re-
moval of duplicates (n = 9), removal of those not meet-
ing screening eligibility criteria (n = 118) and full-text
exclusions (n = 6; see Additional file 3), 14 studies were
included in this review (two RCTs and 12 observational
studies) [18-31].
A search of the grey literature revealed two abstracts
presented at an international conference [32,33]. The
first was for a retrospective analysis of 325 patients with
ARDS and acute kidney injury treated with continuous
renal replacement therapy with or without ECCO2R [32].
The second abstract described a study of 10 patients
using percutaneous extracorporeal lung assist com-
bined with continuous renal replacement therapy [33].
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Figure 1 Literature search. LILACS, Literatura Latino Americana em Ciências da Saúde.
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neither abstract was included in our analysis.
One health technology assessment of an arteriovenous
ECCO2R device was identified [34].
Characteristics of included studies
In total, 14 studies were included: two RCTs (Table 1)
[18,19], and six prospective observational studies [20-25]
and six retrospective studies [26-31] (Table 2). The earli-
est study dated from 1986 and the most recent from
2013. Among included studies, nine were from
Germany, two were from France, two were from Italy,
and one was from the United States. All of the studies
were published in peer-reviewed journals. Only onestudy was multicentre in design [19]. The population
studied was defined as ARDS in 13 studies and acute re-
spiratory failure in one study [24].
The configuration of ECCO2R differed across studies,
with seven using arteriovenous circuits and seven using
venovenous circuits. Only one study conducted after
2000 examined the use of a venovenous device [21]. In
total this systematic review included analysis of 335 pa-
tient cases of arteriovenous ECCO2R and 160 cases of
venovenous ECCO2R.
Risk of bias in included studies
Given the nature of the intervention, neither RCT was
blinded to allocation. Both RCTs reported an intention-
Table 1 Description of included randomised controlled trials
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C, control group; CPPV, conventional positive pressure ventilation; I, intervention group; iLA, interventional lung assist; LFPPV, low-frequency positive-pressure ventilation; LOS, length of stay; NR, not recorded; PCIRV,
pressure controlled inverse ratio ventilation; RRT, renal replacement therapy; VV ECCO2R, venovenous extracorporeal carbon dioxide removal.
aIntervention (control). bVentilator-free days at 28 days (60 days).












Table 2 Description of included nonrandomised studies
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AV, arteriovenous; CRRT, continuous renal replacement therapy; LOS, length of stay; NR, not recorded; VV, venovenous.
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all domains, except in Morris and colleagues’ paper
where the sequence generation was unclear [18]
(Table 3). Both RCT studies halted recruitment earlier than
planned, as in both cases interim analysis concluded that the
difference between new and control therapies was too small
for a significant survival improvement to be demonstrated.
The Xtravent study by Bein and colleagues presented
an overall low risk of bias [19] (Table 3). Although the
initial sample size calculation conducted by the Xtravent
trialists suggested that 120 patients (53 patients per
group for a power of 0.8 and an alpha of 0.05) would
need to be recruited to identify a significant increase in
28-day VFDs (the primary outcome measure), following
a planned interim analysis after enrolment of 56 patientsTable 3 Risk of bias and methodological quality assessment o
Study Sequence generation Allocation conce
Bein and colleagues [19] Low Low
Morris and colleagues [18] Unclear Low
aTrial stopped early due to futility. bTrial stopped early after an interim analysis shothe study period was limited to 3 years because a signifi-
cant difference was not likely to be shown in the
planned cohort. At conclusion, the study had enrolled
79 patients.
The study by Morris and colleagues was judged to
present a low risk of bias [18] (Table 3). The study
aimed to recruit 60 patients, but was halted after 40 par-
ticipants were enrolled. This occurred after a pre-
defined interim analysis concluded that the survival dif-
ference between the intervention and control therapies
was too small for a significant difference to be demon-
strated with 60 randomised patients. Analysis after 40
patients found a small difference in survival between the
control group and the ECCO2R group (mean survival,
30% in ECCO2R patients versus 39% in controls), and itf included randomised controlled trials
alment Selective outcome reporting Other bias Summary
Low Lowa Low
Low Lowb Low
wed treatment effect too small to be demonstrated by proposed sample size.
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demonstrate statistical significance.
Effect of interventions
Given the variation in study designs a meta-analysis was
considered to be inappropriate and data were descrip-
tively synthesised.
Primary outcome
Mortality was the primary outcome. Thirteen studies
presented data on mortality [18-20,22-31]. Neither RCT
demonstrated a statistically significant difference in hos-
pital mortality for those undergoing ECCO2R. Interest-
ingly, the latest RCT reported a relatively low mortality
(control group, 15%; ECCO2R group, 18%), which is in
keeping with mortality figures from other recent ARDS
studies [35], suggesting that overall survival from ARDS
is improving. The observational studies reported mortal-
ity rates ranging from 27 to 75% (mean 55.5%, standard
deviation 47.2 to 60.3).
Secondary outcomes
Ventilator-free days
Two studies reported VFDs [18,27]. The primary out-
come measure in the Xtravent study was VFDs to 28
and 60 days [19]. Subgroup analysis of those patients
with partial pressure of arterial oxygen (PaO2)/fraction
of inspired oxygen (FiO2) <150 demonstrated a signifi-
cant increase in VFDs in those receiving ECCO2R at
both 28 and 60 days (mean ± standard deviation 11.3 ±
7.5 versus 5 ± 6.3 days, P = 0.033 and 40.9 ± 12.8 versus
28.2 ± 16.4 days, P = 0.033, respectively). This increase in
VFDs was not seen in patients with higher PaO2/FiO2
ratios.
Duration of ICU stay and organ failure-free days
Five studies (two RCTs and three retrospective studies)
reported ICU length of stay [18,19,26,27,29]. Neither
RCT demonstrated a significant reduction in ICU length
of stay. Both RCTs also reported hospital length of stay,
but did not demonstrate a difference between groups.
Only the Xtravent study reported on organ failure-free
days, and demonstrated no difference between groups [19].
Respiratory parameters including carbon dioxide removal
Significant variation existed in the respiratory parame-
ters measured among studies (Table 4). Several studies
reported comparative analysis of respiratory parameters
between survivors and nonsurvivors of ECCO2R
[24,27,28], whilst other studies reported measurements
at varying time points, from 2 hours after initiation of
ECCO2R to its discontinuation.
The Xtravent study demonstrated a significant reduc-
tion in tidal volume, minute ventilation and ΔP (plateaupressure – positive end-expiratory pressure) in the
ECCO2R group, which was sustained across several days
of therapy [19]. Morris and colleagues also reported a
sustained reduction in tidal volume in those undergoing
ECCO2R, with an initial improvement in peak inspira-
tory pressures [18]. In both RCTs, tidal volumes ap-
proaching 3 ml/kg predicted body weight were achieved
at least in the initial period after initiation of ECCO2R.
Nonrandomised studies reported outcomes at varying
times after commencing ECCO2R ranging from 2 hours
[28] to decannulation [29]. In the early period (to day 1),
all showed reductions in tidal volume, peak inspiratory
pressure, arterial partial pressure of carbon dioxide and
increase in arterial pH. The level of positive end-
expiratory pressure administered to patients remained
largely unchanged in the majority of studies. The PaO2/
FiO2 ratio increased in all but three studies [19,24,25].
Carbon dioxide removal was quantitatively possible
using strategies of arteriovenous carbon dioxide removal
[19,21,26,29] (Table 4).Complications
All but one study [22] reported on complications en-
countered with ECCO2R therapy (Table 5). Complication
rates ranged from 0 to 25%. Five studies reported rates
in excess of 20% [21,27-30]. Amongst studies examining
arteriovenous devices, the most common complication
was lower limb ischaemia secondary to arterial cannula-
tion. In the majority of studies this was a transient com-
plication, but five cases of compartment syndrome and
one case of lower limb amputation were reported. In
studies where venovenous ECCO2R was used, clotting
within the circuit is the main complication, with catheter
and membrane malfunction also reported. Studies con-
ducted before 2000 (all using venovenous ECCO2R;
Table 5) report higher rates of diffuse bleeding or at sites
other than that where cannula insertion has occurred.
Several studies reported on transfusion requirements
in those receiving ECCO2R. The Xtravent trialists [19]
described a significant increase in the requirement for
red cell transfusion in the ECCO2R group, between ran-
domisation and day 10, compared with the control
group (3.7 ± 2.4 versus 1.5 ± 1.3 units, P < 0.05). Like-
wise, Morris and colleagues reported a significantly
higher red cell transfusion rate in those undergoing
ECCO2R versus controls (11.1 ± 2.3 versus 3.6 ± 0.8 l/
ICU stay) [18].Impact on sedation/analgesia
Two studies reported on sedative/analgesic requirements
[19,26]. In the Xtravent study, ECCO2R patients had a
lower cumulative dose of opioid and benzodiazepine
than those in the control group [19]. Similarly in
Table 4 Principal respiratory outcomes in nonrandomised studies






Vt reduction pH change
Forster and
colleagues [25]
4 hours 68.00 ± 8.28 to 49.6 ±
6.18
NR 19.8 ± 2.0 to 19.0 ±
2.4
8.41 ± 0.30 to 8.34 ±
1.04




Day 1 80.0 ± 23.0 to 54.0 ±
19.0
100.0 ± 28.9 to 120.7
± 51.2
34.0 ± 3.0b to 28.3 ±
4.0
292.5 ± 94.0a to 183.0
± 67.0




NR 120 (81.9 to 152.5) to
60.3 (52.5 to 69)
121.5 (79.3 to 178.3)
to 87 (73 to 139.3)
39 (34.8 to 43.3) to
31.5 (28.8 to 33.5)
5.2 (4.4 to 5.9) to 3.5
(3.1 to 4.3)b
7.06 (6.9 to 7.3) to
7.38 (7.18 to 7.48)
Zimmermann and
colleagues [20]
24 hours 73 (61 to 86) to 41
(34 to 48)
75 (62 to 130) to 110
(86 to 160)
35 (31 to 38) to 30
(26 to 34)
6.6 (5.3 to 7.2) to 4.4
(3.4 to 5.4)b
7.23 (7.16 to 7.30) to
7.44 (7.37 to 7.45)
Terragni and
colleagues [21]
NR 47.2 ± 8.6 to 73.6 ±
11.1




12 hours 65.26 (54 to 72) to
39.8 (36 to 42)
61.6 (47.3 to 85.6) to
135.8 (87.8 to 153)
NR 450 (400 to 542.5) to
200 (145 to 250)a
7.25 (7.22 to 7.29) to
7.4 (7.37 to 7.42)
Bein and colleagues
[28]
24 hours 60 (48 to 80) to 34
(30 to 39)
58 (47 to 78) to 107
(74 to 142)
NR 430 (360 to 540) to
380 (320 to 470)a
7.27 (7.18 to 7.36) to
7.45 (7.41 to 7.50)
Liebold and
colleagues [30]
24 hours 59 ± 17 to 32 ± 8 50 to 110 NR NR NR
Guinard and
colleagues [22]
NR NR NR NR NR NR
Brunet and
colleagues [23]





NR NR NR NR NR NR
Gattinoni and
colleagues [24]
NR NR NR NR NR NR
Data presented as mean ± standard deviation or median (range). NR, not recorded; FiO2, fraction of inspired oxygen; PaCO2, partial pressure of arterial carbon
dioxide; PaO2, partial pressure of arterial oxygen; Pinsp, inspiratory pressure; Pplat, plateau pressure; Vt, tidal volume.
aUnits are millilitres. bUnits
are millilitres/kilogram.
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quired lower doses of opioid (fentanyl: 8.9 to 4.4 mg/kg/
hour) and benzodiazepine (midazolam: 0.28 to 0.19 mg/
kg/hour) after 4 days of ECCO2R treatment [26].
Biomarkers
The role of biomarkers in predicting severity or mortal-
ity from ARDS is not straightforward. Attempts to iden-
tify a biomarker for ARDS have not thus far been
successful [36,37].
Only two of the included studies [19,21] evaluated the
use of ECCO2R and biomarkers, and neither dataset was
complete. The Xtravent study measured serum levels of
proinflammatory cytokines tumour necrosis factor alpha,
IL-6 and IL-8 in 20 patients who underwent ECCO2R
and in 15 controls [19]. IL-6 levels decreased in the
ECCO2R group in the first 24 hours. Tumour necrosis
factor alpha and IL-8 were unchanged. The study by
Terragni and colleagues included assessment of IL-6, IL-8,
IL-1b, and IL-1ra in 10 patients with higher plateau pres-
sure of 28 to 30, and in 15 of 22 patients with lower plat-
eau pressures [21]. In patients with higher plateau
pressures, the use of ECCO2R to facilitate a reduction in
pressure was associated with a significant reduction in
pulmonary inflammatory mediators. This associationsuggests that inflammatory cytokines may be a useful sur-
rogate outcome in phase 2 studies, although it is unclear
whether a change in inflammatory cytokines translates
into improved clinical outcomes.
Discussion
This comprehensive systematic review examined two
RCTs and 12 observational studies that treated 495 pa-
tients with acute respiratory failure with ECCO2R and
found a paucity of high-quality clinical trials evaluating
its use. Differing modalities of ECCO2R were compared,
with arteriovenous ECCO2R being used in seven studies
and venovenous ECCO2R in seven studies.
Our findings indicate that robust data supporting the
use of these devices are lacking. Both RCTs were termi-
nated early for futility and therefore it was not possible
to determine an effect on mortality. Although no mor-
tality benefit was shown, a post hoc analysis of the most
recent RCT [19] indicated that a subset of patients with
moderately severe ARDS demonstrated a trend towards
more VFDs at 60 days and a shorter ICU length of stay.
This post hoc analysis aids in determining optimal indi-
cations for use and design of future trials.
Patients with more severe respiratory failure (PaO2/FiO2
< 150) may be an appropriate population of patients to
Table 5 Complications of extracorporeal carbon dioxide removal










2013 AV 7.5 1× lower limb ischaemia, 2× aneurysm
Nierhaus and
colleagues [29]
2011 AV 21.4 2× catheter displacement, 1× bleeding at insertion site
Weber-Carstens and
colleagues [26]
2009 AV 6.3 1× transient occlusion of femoral artery during cannulation
Zimmermann and
colleagues [20]












2006 AV 24.4 9× lower limb ischaemia, 4× cannula thrombosis, 4× compartment syndrome, 2×








1997 VV NR NR
Morris and
colleagues [18]
1994 VV NR 21× non-CNS haemorrhage (7 requiring discontinuation of ECCO2R), 4× circuit clotting
Brunet and
colleagues [23]
1994 VV 18.2 1× alveolar haemorrhage, 1× diffuse bleeding
Bindslev and
colleagues [31]
1991 VV NR 1× allergic reaction
Gattinoni and
colleagues [24]
1986 VV NR 3× intra-pulmonary bleeding
AV, arteriovenous; CNS, central nervous system; CRRT, continuous renal replacement therapy; ECCO2R, extracorporeal carbon dioxide removal; NR, not reported;
VV, venovenous.
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better risk–benefit profile in more severely ill patients, who
are at a high risk of dying. Data from the UK Intensive Care
National Audit and Research Centre (ICNARC), which col-
lects information from 95% of ICUs in the United King-
dom, found that more than 18,500 of approximately
130,000 mechanically ventilated patients in 2012 had PaO2/
FiO2 < 150. This cohort had a 40% ICU mortality and al-
most 50% hospital mortality. These results provide an esti-
mation of the population who might benefit from ECCO2R
if proven to be effective in this cohort.
Complication rates varied across the papers but the
pattern suggested that increasing familiarity led to lower
rates of complications. Comparing the Zimmermann
and colleagues [20] and Bein and colleagues [28] non-
randomised papers from the same single centre in Re-
gensburg, Germany, complication rates decreased from
24.4% in the earlier period to 11.9% in the prospective
study. This highlights the importance of training in the
introduction of the technology, and perhaps limiting its
use to sites with expertise. Earlier studies demonstrateda high rate of haemorrhagic complications due to the
need for systemic anticoagulation, particularly in older
venovenous circuits. Newer circuits have heparin-
bonded surfaces, which obviates this need. With this
novel technology, there has been a decrease in bleeding
rates, as demonstrated by Knoch and colleagues in 1992
[38], although bleeding remains a risk.
The increasing red cell requirement, reported not only
in the Morris and colleagues study [18] but also in the
more recent Xtravent study [19], represents a meaning-
ful concern regarding ECCO2R use. There is evidence
that red cell transfusion is associated with increased de-
velopment of ARDS [39], and increasing mortality for
critically ill patients [40]. Future study of these devices
should assess need for red cell transfusion carefully.
Both the Xtravent study [19] and the Weber-Carstens
and colleagues study [26] showed decreased need for sed-
ation and analgesia in patients with application of ECCO2R;
lower sedation levels have previously been associated with
shorter ventilation time, shorter ICU and hospital stays,
and lower mortality rates [41,42].
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apy. Morris and colleagues’ study estimated an increase
in hospital costs of approximately 20% per day for
ECCO2R versus control patients [18]; this was probably
an underestimate because increased technical staffing
costs were not included. Gattinoni and colleagues’
study demonstrated that ECCO2R in the 1980s was as-
sociated with a doubling of cost per day of ICU therapy
[24]. Bindslev and colleagues’ 1991 study estimated that
the daily cost of a patient on extracorporeal assistance
is approximately three times greater than that for a
standard ICU bed [31]. None of the other studies dis-
cussed here included a formal economic analysis. The
potential benefits of this therapy are not yet proven,
and certainly concerns still exist about its efficacy, side
effects and costs. Further clinical trials should also
include a health economic analysis to determine the
cost-effectiveness of ECCO2R.
Carbon dioxide removal is quantitatively possible
using strategies of ECCO2R, as reported in almost all of
the studies. The Xtravent RCT and recent nonrando-
mised studies demonstrate that ventilation with very low
tidal volume ventilation was feasible and safe with
ECCO2R. While in some models respiratory acidosis has
been shown to decrease pulmonary inflammatory cyto-
kines [43], this may be attributable to an improvement
in shear stress, and the role of hypercapnic acidosis in
this setting is incompletely understood. Robust studies
have demonstrated reductions in inflammatory cytokines
[21,44] and improved outcomes [3] as a consequence of
lower tidal volume ventilation. In addition, in the clinical
situation, where respiratory and metabolic acidosis may
co-exist, buffering or control of acidosis may be required
in patients intolerant of acidaemia; for example, trau-
matic brain injury. This is an important point in consider-
ing the design of future clinical trials of ECCO2R where
the primary objective should be limitation of injurious
ventilation rather than reversal of respiratory acidosis.
The optimal timing for use of ECCO2R remains un-
clear, although retrospective analysis has shown that a
shorter period of mechanical ventilation (3 versus 5 days)
before application of the device is associated with an im-
proved mortality rate [20]. One group used ECCO2R as
a rescue strategy following prolonged ventilation (9.9 ±
6.2 days) [22] and mortality rates were particularly high
in this group (75%).
The strength of this review is that we adhered closely
to our protocol, which outlined our procedures for mini-
mising bias in the review: these included independent
screening for study inclusion, data extraction and assess-
ment of quality by two authors. With the assistance of
an experienced librarian, we conducted a thorough
search strategy and believe we have identified all relevant
studies.Although the recent RCT has added useful informa-
tion on current ECCO2R use as a well-designed multi-
centre study with a low risk of bias [19], there is still a
paucity of high-quality evidence in this area, and a need
for adequately powered clinical studies. This is an area
where rapid technological advances have been made in
the last 10 years, representing major changes in the
component sophistication and efficacy of ECCO2R. This
confounds attempts to compare devices when a system-
atic review is attempted. Differences in vascular access,
pumped versus nonpumped systems, cardiovascular status
of the patient, need for full anti-coagulation, and more ef-
ficient modern extraction abilities all complicate analysis.
Our work has some limitations, including those com-
mon to all systematic reviews. We are reliant on the
available evidence, and over one-half of included studies
were case series, which are graded as 3 (that is, low-
quality evidence) [45] (Table 2). Only two RCTs on the
use of ECCO2R (graded as level 1+) were conducted,
both of which stopped early and had a time interval of
19 years between them and associated differences in
practice. As such, they offer limited information to in-
form practice. A formal meta-analysis of the data was
not possible because there were only two RCTs with sig-
nificant heterogeneity within those studies.
The UK National Institute of Clinical Evidence guide-
lines on ECCO2R state that ‘evidence on its efficacy is
limited in quantity and quality’ [46]. The 2010 Canadian
Health Technology Assessment found that arteriovenous
ECCO2R is efficacious regarding carbon dioxide removal
and can therefore facilitate lung protective ventilator
strategies, but like our review it found no evidence of
improved long-term survival [34].
We found two ongoing studies. First is a clinical trial
that is currently recruiting in Turin, with the aim of
comparing ultra-low tidal volume ventilation (4 ml/kg
predicted body weight) with low tidal volume ventilation
(6 ml/kg predicted body weight), using ECCO2R to fa-
cilitate this [47]. This is a randomised nonblinded study,
with the aim to recruit 230 patients over 12 to
18 months. The other ongoing study is recruiting to as-
sess ECCO2R combined with early renal replacement
therapy [48]. The Xtravent study was conducted in 10
centres over 40 months and yet only 79 patients were
enrolled [19], underlining the difficulties of enrolment in
this patient population.
Our review indicates a state of clinical equipoise on the
benefits of ECCO2R in acute respiratory failure. There is a
trend towards improved outcomes as indicated by more
VFDs with the application of modern ECCO2R in patients
with more severe disease; however, definitive data are as yet
lacking. Questions regarding the optimal device, timing
and patient selection will be best answered by further
rigorous and well-designed RCTs.
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ECCO2R is an area of rapidly evolving technology and in-
creasing rates of utilisation. As physicians, nurses and tech-
nical staff gain familiarity with this technology, its use is
likely to increase. As a treatment modality for respiratory
failure and ARDS, ECCO2R is efficacious as a treatment for
hypercapnia, facilitating ultra-low tidal volume ventilation.
There is some indication that patients with moderately se-
vere disease in whom ECCO2R is employed at an early stage
may benefit. However, evidence for a reduction in mortality
and other important clinical outcomes is still lacking.
Additional files
: The full MEDLINE search strategy.
: The pre-piloted data extraction form.
: A table presenting excluded articles [49-54].
Abbreviations
ARDS: Acute respiratory distress syndrome; ECCO2R: Extracorporeal carbon
dioxide removal; FiO2: Fraction of inspired oxygen; ICNARC: Intensive Care
National Audit and Research Centre; IL: Interleukin; LILACS: Literatura Latino
Americana em Ciências da Saúde; PaO2: Partial pressure of arterial oxygen;
RCT: Randomised controlled trial; VFD: Ventilator-free day.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JJM, DFM, MF and BB conceived the review. All authors made a substantial
contribution to the protocol development. MF and JM extracted the data
and drafted the manuscript. All authors were involved in analysis and
interpretation of data, critically revised the manuscript and approved the
final manuscript.
Acknowledgements
The authors wish to thank the Intensive Care Foundation for their help and
support; and also Richard Fallis, Medical Librarian in the Medical Library of
the Royal Victoria Hospital Belfast, for his help in designing and
implementing the search strategy. The data quoted from ICNARC derive
from the Case Mix Programme Database. The Case Mix Programme is the
national, comparative audit of patient outcomes from adult critical care
coordinated by ICNARC. These analyses are based on data for 133,266
admissions to 203 adult, general critical care units based in National Health
Service hospitals geographically spread across England, Wales and Northern
Ireland. For more information on the representativeness and quality of these
data, please contact ICNARC.
Published:
References
1. Villar J, Blanco J, Anon JM, Santos-Bouza A, Blanch L, Ambros A, Gandia F,
Carriedo D, Mosteiro F, Basaldua S, Fernandez RL, Kacmarek RM, ALIEN
Network: The ALIEN study: incidence and outcome of acute respiratory
distress syndrome in the era of lung protective ventilation. Intensive Care
Med 2011, 37:1932–1941.
2. Tremblay LN, Slutsky AS: Ventilator-induced lung injury: from the bench
to the bedside. Intensive Care Med 2006, 32:24–33.
3. ARDS Network: Ventilation with lower tidal volumes as compared with
traditional tidal volumes for acute lung injury and the acute respiratory
distress syndrome. N Engl J Med 2000, 342:1301–1308.
4. Rubenfeld GD, Cooper C, Carter G, Thompson BT, Hudson LD: Barriers to
providing lung-protective ventilation to patients with acute lung injury.




15 May 20145. Cove ME, Maclaren G, Federspiel WJ, Kellum JA: Bench to bedside review:
Extracorporeal carbon dioxide removal, past present and future. Crit Care
2012, 16:232.
6. Gattinoni L, Kolobow T, Tomlinson T, Iapichino G, Samaja M, White D, Pierce J:
Low-frequency positive pressure ventilation with extracorporeal carbon
dioxide removal (LFPPV-ECCO2R): an experimental study. Anesth Analg 1978,
57:470–477.
7. Gattinoni L, Kolobow T, Tomlinson T, White D, Pierce J: Control of
intermittent positive pressure breathing (IPPB) by extracorporeal
removal of carbon dioxide. Br J Anaesth 1978, 50:753–758.
8. Brunet F, Belghith M, Mira JP, Lanore JJ, Vaxelaire JF, Dall'ava Santucci J,
Dhainaut JF: Extracorporeal carbon dioxide removal and low-frequency
positive-pressure ventilation. Improvement in arterial oxygenation with
reduction of risk of pulmonary barotrauma in patients with adult
respiratory distress syndrome. Chest 1993, 104:889–898.
9. Moerer O, Quintel M: Protective and ultra-protective ventilation: using
pumpless interventional lung assist (iLA). Minerva Anestesiol 2011,
77:537–544.
10. Fitzgerald M, Millar J, Blackwood B, Davies A, Brett SJ, McAuley DF,
McNamee JJ: Effectiveness of extra-corporeal CO2 removal for patients
with respiratory failure secondary to adult respiratory distress syndrome.
PROSPERO International Prospective Register of Systematic Reviews.
[http://www.crd.york.ac.uk/NIHR_PROSPERO/].
11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M,
Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate healthcare
interventions: explanation and elaboration. BMJ 2009, 339:b2700.
12. ClinicalTrials. [http://www.clinicaltrials.gov].
13. Current Controlled Trials. [http://www.controlled-trials.com].
14. NIHR Portal. [http://www.portal.nihr.ac.uk].
15. UK Critical Appraisal Skills Programme. [http://www.casp-uk.net].
16. Chan K, Bhandari M: Three-minute critical appraisal of a case series.
Indian J Orthop 2011, 45:103–104.
17. Cochrane Handbook for Systematic Reviews of Interventions Version
5.1.0. [www.cochrane-handbook.org].
18. Morris AH, Wallace CJ, Menlove RL, Clemmer TP, Orme JF Jr, Weaver LK,
Dean NC, Thomas F, East TD, Pace NL, Suchyta MR, Beck E, Bombino M,
Sittig DF, Böhm S, Hoffmann B, Becks H, Butler S, Pearl J, Rasmusson B:
Randomized clinical trial of pressure-controlled inverse ratio ventilation
and extracorporeal CO2 removal for adult respiratory distress syndrome.
Am J Respir Crit Care Med 1994, 149(2 Pt 1):295–305.
19. Bein T, Weber-Carstens S, Goldmann A, Müller T, Staudinger T, Brederlau J,
Muellenbach R, Dembinski R, Graf BM, Wewalka M, Philipp A, Wernecke KD,
Lubnow M, Slutsky AS: Lower tidal volume strategy (≈3 ml/kg) combined
with extracorporeal CO2 removal versus ‘conventional’ protective
ventilation (6 ml/kg) in severe ARDS: the prospective randomized
Xtravent-study. Intensive Care Med 2013, 39:847–856.
20. Zimmermann M, Bein T, Arlt M, Philipp A, Rupprecht L, Mueller T, Lubnow M,
Graf BM, Schlitt HJ: Pumpless extracorporeal interventional lung assist in
patients with acute respiratory distress syndrome: a prospective pilot
study. Crit Care 2009, 13:R10.
21. Terragni PP, Del Sorbo L, Mascia L, Urbino R, Martin EL, Birocco A, Faggiano
C, Quintel M, Gattinoni L, Ranieri VM: Tidal volume lower than 6 ml/kg
enhances lung protection: role of extracorporeal carbon dioxide
removal. Anesthesiology 2009, 111:826–835.
22. Guinard N, Beloucif S, Gatecel C, Mateo J, Payen D: Interest of a therapeutic
optimization strategy in severe ARDS. Chest 1997, 111:1000–1007.
23. Brunet F, Mira JP, Belghith M, Monchi M, Renaud B, Fierobe L, Hamy I,
Dhainaut JF, Dall'ava-Santucci J: Extracorporeal carbon dioxide removal
technique improves oxygenation without causing overinflation.
Am J Respir Crit Care Med 1994, 149:1557–1562.
24. Gattinoni L, Pesenti A, Mascheroni D, Marcolin R, Fumagalli R, Rossi F,
Iapichino G, Romagnoli G, Uziel L, Agostoni A, Kolobow T, Damia G:
Low-frequency positive-pressure ventilation with extracorporeal CO2
removal in severe acute respiratory failure. JAMA 1986, 256:881–886.
25. Forster C, Schriewer J, John S, Eckardt KU, Willam C: Low-flow CO2 removal
integrated into a renal-replacement circuit can reduce acidosis and
decrease vasopressor requirements. Crit Care 2013,
17:R154.
26. Weber-Carstens S, Bercker S, Hommel M, Deja M, MacGuill M, Dreykluft C,
Kaisers U: Hypercapnia in late-phase ALI/ARDS: providing spontaneous
Fitzgerald et al. Critical Care Page 11 of 112014, 18:222
http://ccforum.com/content/18/3/222breathing using pumpless extracorporeal lung assist. Intensive Care Med
2009, 35:1100–1105.
27. Muellenbach RM, Kredel M, Wunder C, Küstermann J, Wurmb T, Schwemmer U,
Schuster F, Anetseder M, Roewer N, Brederlau J: Arteriovenous extracorporeal
lung assist as integral part of a multimodal treatment concept: a
retrospective analysis of 22 patients with ARDS refractory to standard care.
Eur J Anaesthesiol 2008, 25:897–904.
28. Bein T, Weber F, Philipp A, Prasser C, Pfeifer M, Schmid FX, Butz B, Birnbaum D,
Taeger K, Schlitt HJ: A new pumpless extracorporeal interventional lung
assist in critical hypoxemia/hypercapnia. Crit Care Med 2006, 34:1372–1377.
29. Nierhaus A, Frings D, Braune S, Baumann HJ, Schneider C, Wittenburg B,
Kluge S: Interventional lung assist enables lung protective mechanical
ventilation in acute respiratory distress syndrome. Minerva Anestesiol 2011,
77:797–801.
30. Liebold A, Philipp A, Kaiser M, Merk J, Schmid FX, Birnbaum DE: Pumpless
extracorporeal lung assist using an arterio-venous shunt. Applications
and limitations. Minerva Anestesiol 2002, 68:387–391.
31. Bindslev L, Böhm C, Jolin A, Hambraeus Jonzon K, Olsson P, Ryniak S:
Extracorporeal carbon dioxide removal performed with surface-
heparinized equipment in patients with ARDS. Acta Anaesthesiol Scand
Suppl 1991, 95:125–130.
32. Mattei N, Mocavero P, Corcione A: Extracorporeal CO2 removal in ICU
[abstract]. Eur J Anaesthesiol 2011, 28(Suppl):170.
33. Atalan HK, Dumantepe M, Denizalti TB, Tarhan IA, Ozler A: Combined use
of pumpless extracorporeal lung assist system and continuous renal
replacement therapy with citrate anticoagulation in polytrauma patients
[abstract]. Crit Care 2013, 17(Suppl):S23.
34. Health Quality Ontario: Extracorporeal lung support technologies – bridge
to recovery and bridge to lung transplantation in adult patients: an
evidence-based analysis. Ont Health Technol Assess Ser 2010, 10:1–47.
35. Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, Scales DC,
Stather DR, Li A, Jones A, Gattas DJ, Hallett D, Tomlinson G, Stewart TE,
Ferguson ND: Has mortality from acute respiratory distress syndrome
decreased over time? A systematic review. Am J Respir Crit Care Med 2009,
179:220–227.
36. Terpstra ML, Aman J, van Nieuw Amerongen GP, Groeneveld AB: Plasma
biomarkers for acute respiratory distress syndrome: a systematic review
and meta-analysis. Crit Care Med 2014, 42:691–700.
37. Tzouvelekis A, Pneumatikos I, Bouros D: Serum biomarkers in acute
respiratory distress syndrome an ailing prognosticator. Respir Res 2005,
6:62.
38. Knoch M, Köllen B, Dietrich G, Müller E, Mottaghy K, Lennartz H: Progress in
veno-venous long-term bypass techniques for the treatment of ARDS.
Controlled clinical trial with the heparin-coated bypass circuit. Int J Artif
Organs 1992, 15:103–108.
39. Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani D:
Clinical predictors of and mortality in acute respiratory distress
syndrome: potential role of red cell transfusion. Crit Care Med 2005,
33:1191–1198.
40. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G,
Tweeddale M, Schweitzer I, Yetisir E, Transfusion Requirements in Critical
Care Investigators, Canadian Critical Care Trials Group: A multicenter,
randomized, controlled clinical trial of transfusion requirements in
critical care. N Engl J Med 1999, 340:409–417.
41. Strøm T, Martinussen T, Toft P: A protocol of no sedation for critically ill
patients. Lancet 2010, 375:475–480.
42. Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, McArthur C,
Seppelt IM, Webb S, Weisbrodt L, Sedation Practice in Intensive Care
Evaluation (SPICE) Study Investigators; ANZICS Clinical Trials Group: Early
intensive care sedation predicts long-term mortality in ventilated
critically ill patients. Am J Respir Crit Care Med 2012, 186:724–731.
43. Laffey JG, Honan D, Hopkins N, Hyvelin JM, Boylan JF, McLoughlin P:
Hypercapnic acidosis attenuates endotoxin-induced acute lung injury.
Am J Respir Crit Care Med 2004, 169:46–56.
44. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, Bruno F,
Slutsky AS: Effect of mechanical ventilation on inflammatory mediators in
patients with acute respiratory distress syndrome: a randomized
controlled trial. JAMA 1999, 282:54–61.
45. Harbour R, Miller J, Scottish Intercollegiate Guidelines Network Grading
Review Group: A new system for grading recommendations in evidence
based guidelines. BMJ 2001, 323:334–336.46. Extracorporeal Membrane Carbon Dioxide Removal. NICE interventional
Procedure Guidance 428. [http://guidance.nice.org.uk/ipg428].
47. Flow-flow ECCO2-R and 4 ml/kg Tidal Volume vs. 6 ml/kg Tidal Volume
to Enhance Protection From VILI in Acute Lung Injury. [http://clinicaltrials.
gov/ct2/show/NCT01522599?term=NCT01522599&rank=1].
48. Pulmonary and Renal Support During Acute Respiratory Distress
Syndrome. [http://clinicaltrials.gov/ct2/results?term=NCT01239966&Search=
Search].
Cite this article as: Fitzgerald et al.: Extracorporeal carbon dioxide
removal for patients with acute respiratory failure secondary to the
acute respiratory distress syndrome: a systematic review. Critical Care
10.1186/cc13875
2014, 18:222
